The Impact of Symptom Interference Using the MD Anderson Symptom Inventory-Brain Tumor Module (MDASI-BT) on Prediction of Recurrence in Primary Brain Tumor Patients

被引:42
|
作者
Armstrong, Terri S. [1 ,2 ]
Vera-Bolanos, Elizabeth [2 ]
Gning, Ibrahima [3 ]
Acquaye, Alvina [2 ]
Gilbert, Mark R. [2 ]
Cleeland, Charles [3 ]
Mendoza, Tito [3 ]
机构
[1] Univ Texas Hlth Sci Ctr, Sch Nursing, Dept Integrat Nursing Care, Houston, TX USA
[2] Univ Texas MD Anderson Canc Ctr, Dept Neurooncol, Houston, TX 77030 USA
[3] Univ Texas MD Anderson Canc Ctr, Dept Symptom Res, Houston, TX 77030 USA
关键词
brain tumor; symptoms; tumor progression; QUALITY-OF-LIFE; PROGNOSTIC-FACTORS; CANCER-PATIENTS; SURVIVAL; SEVERITY; GUIDANCE; CRITERIA; PAIN; PROS; FDA;
D O I
10.1002/cncr.25892
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
BACKGROUND: Tumor grade, age, extent of resection, and performance status are established prognostic factors for survival in primary brain tumor (PBT) patients. Development of disease-related symptoms is predictive of tumor recurrence in other cancers but has not been reported in the PBT population. METHODS: A cross-sectional sample of 294 PBT patients participated. Progression was based on the radiologist report of the magnetic resonance imaging (MRI). The relation of clinical variables (age, extent of resection, tumor grade, and Karnofsky performance status [KPS]) and MD Anderson Symptom Inventory-Brain Tumor Module (MDASI-BT) mean symptom and interference sub-scales with progression was examined using logistic regression. RESULTS: The study enrolled more men (60%, n =175); median age was 46 years. The majority had less than a gross total resection (n = 186, 64%), and a good KPS (KPS >= 90) (N = 208). The majority had a grade 3 or 4 tumor (n = 199) and 24% of patients had recurrence. Tumor grade and activity-related interference were significantly related to progression. Patients with tumor grade 4 were 2.4 times more likely to have recurrence (95% Cl, 1.2-5.; P < .015). Patients with significant (ratings of >= 5) activity-related interference were 3.8 times more likely to have recurrence (95% Cl, 2.14-6.80; P < .001). Mean activity-related score was 4.8 for those with progression on MRI and 2.2 for those with stable disease. CONCLUSIONS: Significant activity-related interference and tumor grade were associated with recurrence but not KPS, age, or extent of resection. These results provide preliminary support for the use of symptom interference in assessment of disease status. Because the authors used a cross-sectional sample, future studies evaluating change over time are needed. Cancer (C) 2011;117:3222-8. 2077 American Cancer Society.
引用
收藏
页码:3222 / 3228
页数:7
相关论文
共 38 条
  • [1] THE IMPACT OF SYMPTOM INTERFERENCE USING THE MD ANDERSON SYMPTOM INVENTORY-BRAIN TUMOR MODULE (MDASI-BT) ON PREDICTION OF RECURRENCE IN PRIMARY BRAIN TUMOR PATIENTS
    Armstrong, Terri
    Vera-Bolanos, Elizabeth
    Gning, Ibrahima
    Acquaye, Alvina
    Gilbert, Mark R.
    Cleeland, Charles
    Mendoza, Tito R.
    NEURO-ONCOLOGY, 2010, 12 : 103 - 103
  • [2] Prediction of progression and performance status: MD Anderson symptom inventory-brain tumor (MDASI-BT) symptom profiles in patients with primary brain tumors
    Armstrong, Terri S.
    Mendoza, Tito
    Cohen, Marlene Z.
    Morrissey, Marilyn
    Gilbert, Mark R.
    Cleeland, Charles
    NEURO-ONCOLOGY, 2006, 8 (04) : 475 - 475
  • [3] Validation of the MD Anderson symptom inventory brain tumor module (MDASI-BT)
    Armstrong, T. S.
    Mendoza, T.
    Gring, I.
    Coco, C.
    Cohen, M. Z.
    Eriksen, L.
    Hsu, M. A.
    Gilbert, M. R.
    Cleeland, C.
    NEURO-ONCOLOGY, 2006, 8 (04) : 474 - 475
  • [4] ASSESSING THE VALIDITY OF THE MD ANDERSON SYMPTOM INVENTORY-BRAIN TUMOR (MDASI-BT) USING CAREGIVER PROXY REPORT
    Gning, Ibrahima
    Armstrong, Terri S.
    Wefel, Jeffrey S.
    Acquaye, Alvina A.
    Vera-Bolanos, Elizabeth
    Mendoza, Tito R.
    Gilbert, Mark R.
    Cleeland, Charles S.
    NEURO-ONCOLOGY, 2012, 14 : 158 - 158
  • [5] Validation of the M.D. Anderson Symptom Inventory Brain Tumor Module (MDASI-BT)
    T.S. Armstrong
    T. Mendoza
    I. Gring
    C. Coco
    M.Z. Cohen
    L. Eriksen
    Ming-Ann Hsu
    M.R. Gilbert
    C. Cleeland
    Journal of Neuro-Oncology, 2006, 80 : 27 - 35
  • [6] Validation of the M.D. Anderson Symptom Inventory Brain Tumor Module (MDASI-BT)
    T. S. Armstrong
    T. Mendoza
    I. Gning
    C. Coco
    M. Z. Cohen
    L. Eriksen
    Ming-Ann Hsu
    M. R. Gilbert
    C. Cleeland
    Journal of Neuro-Oncology, 2006, 80 (1) : 37 - 37
  • [7] Validation of the M.D. Anderson Symptom Inventory Brain Tumor Module (MDASI-BT)
    Armstrong, T. S.
    Mendoza, T.
    Gring, I.
    Coco, C.
    Cohen, M. Z.
    Eriksen, L.
    Hsu, Ming-Ann
    Gilbert, M. R.
    Cleeland, C.
    JOURNAL OF NEURO-ONCOLOGY, 2006, 80 (01) : 27 - +
  • [8] EVALUATING PATIENT SYMPTOM BURDEN USING THE MD ANDERSON SYMPTOM INVENTORY-BRAIN TUMOR (MDASI-BT) IN EARLY PHASE TRIAL OF A MULTI-KINASE INHIBITOR
    Lindsley, Matthew
    Vera, Elizabeth
    Mendoza, Tito
    Wu, Jing
    Armstrong, Terri
    ONCOLOGY NURSING FORUM, 2021, 48 (02) : 31 - 32
  • [9] Reliability and validity of the M.D. Anderson symptom inventory (MDASI-BT) in the primary brain tumor patient population
    Armstrong, TS
    Mendoza, T
    Cohen, MZ
    Morrissey, M
    Gilbert, MR
    Cleeland, C
    NEURO-ONCOLOGY, 2004, 6 (04) : 355 - 356
  • [10] Identifying symptom recurrences in primary brain tumor patients using the MDASI-BT and qualitative interviews
    Alvina A. Acquaye
    Samuel S. Payén
    Elizabeth Vera
    Loretta A. Williams
    Mark R. Gilbert
    Shiao-Pei Weathers
    Terri S. Armstrong
    Journal of Patient-Reported Outcomes, 3